Medscape: Spherical heart may predict heart disease
UC expert comments on new study
A new study found that increased heart sphericity was associated with an increased risk for cardiomyopathy (heart disease), heart failure and atrial fibrillation (irregular heartbeat.)
Richard Becker, MD, professor of medicine in the UC College of Medicine, was not involved in the study and provided analysis to Medscape.
"The main caveat is translating the information directly to patient care," Becker said. "Near-term yield could include using the spherical calculation in routine MRI of the heart, and based on the findings, following patients more closely if there is an abnormal shape. Or performing an MRI and targeted gene testing if there is a family history of cardiomyopathy or [of] an abnormal shape of the heart."
Becker added that it will be important to validate the findings in larger patient populations and evalute how they are affected by patient and environmental factors.
"The study was well done and may serve as a foundation for future research," Becker said. "The investigators used several powerful tools, including MRI, genomics, and [artificial intelligence] to draw their conclusions. This is precisely the way that 'big data' should be used — in a complementary fashion."
Read the Medscape article. (Note: Subscription or login may be needed to access full article.)
Related Stories
UC biologist talks about 'pearmageddon'
March 16, 2026
WLWT talks to UC biologist and Department Head Theresa Culley about invasive, nonnative Callery pear trees that are spreading across Ohio forests after they were introduced by landscapers more than 50 years ago.
Local media highlight completion of Blood Cancer Healing Center fourth and fifth floors
March 16, 2026
Local media including WLWT and the Cincinnati Business Courier highlighted the opening of research laboratories and the UC Osher Wellness Suite and Learning Kitchen at the University of Cincinnati Cancer Center’s Blood Cancer Healing Center.
Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy
March 16, 2026
Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.